Science & Technology Event
Exact Therapeutics is delighted to invite you to our
SCIENCE & TECHNOLOGY EVENT
on March 28, 2023
The unique innovative ultrasound-based Acoustic Cluster Therapy (ACT®) technology will be presented and demonstrated.
Management, board members, and the Principal Investigator of the ACTIVATE clinical study will review opportunities, status, and plans.
Programme:
12.30-13.00 Arrival, coffee, snacks
Demo of the ACT® technology
13.00-13.10
Mr. Anders Wold, Chairman of the Board
EXACT Therapeutics – an attractive opportunity, standing on the shoulders of industry giants
13.10-13.45
Dr. Per Walday, CEO of EXACT Therapeutics
ACT® – a unique technology platform backed by solid science, in an emerging field of healthcare
13.45-14.00
Dr. Amir Snapir, CMO of EXACT Therapeutics
The ACTIVATE study – clinical study and plans forward
14.00-14.20
Prof. Dr. Udai Banerji - P.I. for the ACTIVATE Study
Clinical Experience with the ACT® Technology – The clinician’s perspective
14.20-14.30
Sir Bill Castell, Board member
Closing Remarks – ACT® in the future of precision medicine
14.30 – 15.00
Q&A sessions
Oslo Science Park (Forskningsparken – Faros) Gaustadalléen21, Oslo
For live attendance: Register here
For live streaming: Live Streaming of Event
Our speakers
Anders Wold – Chairman of the Board
Prior to becoming chairman of the Board of Exact Therapeutics, Anders Wold was until 2022 the Business Development and Strategic Advisor to the GE Healthcare President and CEO. He was until Spring 2021 the CEO for GE Healthcare's Global Clinical Care Solution business unit with USD 5 billion in sales and over 5,000 employees. The business unit includes Ultrasound, Patient Monitoring, Anesthesia, Ventilation, Diagnostic Cardiology, Maternal Infant Care, Digital Solutions & Service.
In his 38 years in the Ultrasound industry, Mr Wold has built a fast paced innovation process launching more than 20 new products every year over the last decade. The last new product added to the portfolio was the handheld Ultrasound Vscan Air™.
Dr. Per Walday - CEO of EXACT Therapeutic
A successful senior executive in the healthcare industry, Dr. Walday has broad experience from research to commercialization of diagnostics and therapeutics globally, including drug-device combination within the field of oncology. Dr. Walday joined Exact Therapeutics as CEO in June, 2022, and prior to that he was CEO of PCI Biotech (OSE: PCIB), where he built an effective organization that progressed the platform technology into a pipeline of assets, including late stage clinical programs through FDA and EMA regulatory paths.
Prior to this, Dr. Walday spent almost two decades with Nycomed Imaging and GE Healthcare based in Norway where, as Global Head Project Management, he was responsible for the management of all development programs of new pharmaceutical products. These included R&D efforts within the field of ultrasound and microbubbles which paved the way for what would become years later EXACT-Tx’s Acoustic Cluster Therapy (ACT®). Dr. Walday has a PhD in neurophysiology from the University of Oslo.
Dr. Amir Snapir – CMO of EXACT Therapeutics
Dr. Snapir has extensive experience in global clinical development of novel therapeutics, from early clinical translation to marketing authorisation, combined with extensive international regulatory experience. Dr Snapir also has years of experience in business collaborations, alliances and product co-developments.
Prior to joining Exact Therapeutics in 2022, Dr Snapir held the position as CMO of PCI Biotech where he was responsible for the clinical development of drug-device combination product candidates. From 2007 to 2020 he held various positions at Orion Pharma, Espoo, Finland, spanning from leader of clinical pharmacogenomics to clinical development leader in Oncology. Dr Snapir is the author of numerous scientific publications. Dr Snapir has a PhD from the University of Turku, Finland and an MD from the University of Tel Aviv, Israel.
Prof. Dr. Udai Banerji - P.I. for the ACTIVATE Study
Professor Udai Banerji champions multidisciplinary working at the interface between early phase clinical trials, drug discovery and translational research related to drug resistance.
He has been a principal investigator and a sub-investigator in over 35 and 100 first-in-human studies, respectively.
He joined the ICR in 2000 as a clinical fellow as part of their PhD programme and was awarded his PhD (University of London) in 2005. He started his training in medical oncology at The Royal Marsden in 2003 and was awarded his Certificate of Completion of Training in Medical Oncology in 2007. He joined the ICR as a Career Development Faculty and an honorary consultant at The Royal Marsden in 2007.
He is a key member of the Cancer Therapeutics Unit, providing early clinical insights into areas of unmet need and clinical relevance during target prioritisation. He leads the Clinical Pharmacodynamics Biomarker Group, which plays a crucial role in transferring pharmacodynamic biomarkers used in drug discovery on to platforms that can be used in clinical trials.
Sir William Martin Castell LVO FMedSci - Board member
Sir William Castell LVO, born 10 April 1947, is a British businessman who has pursued a career in innovation in healthcare. A degree in Marketing combined with Chartered Accountancy led to over 20 years at the Wellcome Foundation. First as the Chief Executive of Wellcome Biotech, then as Commercial Director of Wellcome PLC. Bill left Wellcome to become Chief Executive of Amersham in 1989 and led the company until 2004, by which time it had become a force in global diagnostics and life sciences. In 2004, GE Inc acquired Amersham and Bill became a Vice Chairman of General Electric and President of GE Heathcare. Bill then moved to Chair the Wellcome Trust from 2006-2015.
Over the last 20 years Bill has served on a number of prominent industrial Boards including: Marconi PLC; BP PLC as Senior Independent Director; as well as remaining at General Electric as an independent Director until 2011.
His commitment to healthcare has brought him to serve as a Director of the MRC in the UK, the Board of the STS Forum Kyoto in Japan, and the National Bureau of Asian Research in Seattle. He is also focused on communities: Founding Chairman, Regeneration Through Heritage; Chairman of the Prince’s Trust; Founding Chairman of the High Street Fund; Founding Chairman, Foundation for Future London - The Olympic Legacy. Bill chaired Chichester Festival Theatre from 2012-2022 and was a Commissioner on the Royal Commission of 1851 from 2011-2022. He serves on three Boards in healthcare therapy, clinical services, and clinical assays.
He is an Honorary Fellow of the Academy of Medical Sciences and has received recognition of his work with honorary degrees across the UK including Dundee, York, Oxford, Cardiff, Kings, Queen Mary, UCL, Brunel and Imperial, as well as Arizona State University.